Technology

BeiGene

$362.00
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$14.91 (-3.96%) As of 4:10 PM UTC today

Why Robinhood?

You can buy or sell BeiGene and other stocks, options, and ETFs commission-free!

About BGNE

BeiGene, Ltd. American Depositary Shares, also called BeiGene, is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290). The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Beijing, China. The listed name for BGNE is BeiGene, Ltd. American Depositary Shares.

CEO
John V. Oyler
Employees
3,500
Headquarters
Beijing, Beijing
Founded
2010
Market Cap
31.96B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
422.15K
High Today
$368.99
Low Today
$358.17
Open Price
$365.00
Volume
173.95K
52 Week High
$382.20
52 Week Low
$118.55

Collections

BGNE Earnings

-$6.39
-$4.26
-$2.13
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 1

You May Also Like

SZNE
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure